Bruce Keyt
2022
In 2022, Bruce Keyt earned a total compensation of $1.8M as Chief Scientific Officer at IGM Biosciences, a 60% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $219,754 |
|---|---|
| Option Awards | $928,290 |
| Salary | $473,200 |
| Stock Awards | $218,056 |
| Total | $1,839,300 |
Keyt received $928.3K in option awards, accounting for 50% of the total pay in 2022.
Keyt also received $219.8K in non-equity incentive plan, $473.2K in salary and $218.1K in stock awards.
Rankings
In 2022, Bruce Keyt's compensation ranked 1,892nd out of 5,760 executives tracked by ExecPay. In other words, Keyt earned more than 67.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,892 out of 5,760 | 67th |
Division Manufacturing | 1,001 out of 3,136 | 68th |
Major group Chemicals And Allied Products | 418 out of 1,422 | 71st |
Industry group Drugs | 383 out of 1,323 | 71st |
Industry Pharmaceutical Preparations | 274 out of 969 | 72nd |
Source: SEC filing on April 27, 2023.
Keyt's colleagues
We found two more compensation records of executives who worked with Bruce Keyt at IGM Biosciences in 2022.
News
IGM Biosciences CEO Fred Schwarzer's 2022 pay falls 46% to $5.3M
April 27, 2023
IGM Biosciences CEO Fred Schwarzer's 2021 pay jumps 94% to $9.9M
April 27, 2022
IGM Biosciences CEO Fred Schwarzer's 2020 pay jumps 574% to $5.1M
April 29, 2021
IGM Biosciences CEO Fred Schwarzer's 2019 pay jumps 46% to $757K
April 21, 2020